Bayer faces billions in payouts for half century-old toxic mess
Bayer is facing billions of dollars in exposure from a growing number of lawsuits over PCB products. Read more at ...
FiercePharma8h
JPM25: Bayer gears up for 'must-win battles' as Xarelto loss of exclusivity in full swing, says pharma chief
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
Jury orders Bayer to pay $100 million over PCBs in Washington school
A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...
mic19h
Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure
Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to ...
devdiscourse1d
Bayer Ordered to Pay $100 Million in PCB Toxic Chemical Case
A jury in Washington state has ordered Bayer to pay $100 million to four plaintiffs in a lawsuit over exposure to toxic PCBs ...
Jury says Bayer must pay $100M in trial over PCBs in Washington school
Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) must pay $100M to four people who say they were sickened by exposure to toxic PCB chemicals ...
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass ...
Agtech seedlings: Bayer, European refinery to scale US biofuel production
Inari raised $144 million to bring gene-edited seeds to market and an Israel-based startup looks to develop its computer ...
HSF Defends Bayer on Roundup Class Action as Litigation Comes to an End in Australia
In a Federal Court of Australia judgment handed down on Christmas eve, Justice Michael Lee discontinued the class action ...
PharmiWeb2d
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies
Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...